Symptom Management in the last weeks & days of life. Facilitator: Vernon Davis RN/Community Team Leader Rowcroft Community Team

Similar documents
Renal Palliative Care Last Days of Life

SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL

Syringe driver in Palliative Care

PAIN MANAGEMENT Person established taking oral morphine or opioid naive.

GUIDELINES ON THE MANAGEMENT OF PAIN DUE TO CANCER IN ADULTS

PAIN MANAGEMENT Patient established on oral morphine or opioid naive.

Care in the Last Days of Life

PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT

Supporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety

Symptom Control in the Community Setting. Dr Andrew Tysoe-Calnon

Supportive Care. End of Life Phase

Clatterbridge Centre for Oncology

Symptom Management Guidelines for End of Life Care

Mid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care

MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life

Renal Prescribing at End of Life Guidance for Anticipatory prescribing for patients in renal failure (egfr<30) at the end of life

SYRINGE DRIVER MEDICATIONS

GUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT (estimated glomerular filtration rate<30)

Doncaster & Bassetlaw Cancer Locality. Palliative Care Core Formulary

Algorithms for Symptom Management. In End of Life Care

PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE

Palliative Prescribing - Pain

Analgesia. This is widely used in palliative care. It has antipyretic and analgesic effects but no anti-

Conservative Management of Uraemia

Using syringe pumps in palliative care

End of life prescribing guidance

The pain of it all. Rod MacLeod MNZM. Hibiscus Hospice, Auckland and University of Auckland

For patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.

Pain management in palliative care. Dr. Stepanie Lippett and Sister Karen Davies-Linihan

Palliative care in long-term conditions Scottish Palliative Care Pharmacists Association

Regional Renal Training

ANTICIPATORY PRESCRIBING FOR PATIENTS AT END OF LIFE WITH RENAL IMPAIRMENT

BACKGROUND Measuring renal function :

Anticipatory Medications for End of Life Patients. Doses must be proportional to the current analgesic medication YES NO YES NO

GUIDELINES AND AUDIT IMPLEMENTATION NETWORK

Essential Syringe Driver Training for T 34. Elaine Bird St Luke s Hospice

Care of dying adults in the last days of life. Improving care at the very end of life.

Diamorphine 4 hour. alfentanil (500microgram/mL) Calculated by dividing 24 hour oral morphine dose by 30

Palliative care for patients with brain cancer

Palliative care for heart failure patients. Susan Addie

[Type text] Anticipatory Medication STAT dose and Syringe Driver Guidance [Type text]

Palliative Care Impact Survey

Care of the Dying. For dosing in severe renal impairment see separate guidance for care of the dying in severe renal failure.

The last days of life in hospital and at home

Pain management in Paediatric Palliative Care. Dr Jane Nakawesi 14 th August 2017

Analgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015

Managing Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital.

Pain. Christine Illingworth. Community Nurse St Luke s Hospice 17/5/17

Guidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth)


End Stage Liver Disease Regional Audit Casenote Survey

Care of the Dying Management in Severe Renal Failure

Anticipatory prescribing and end of life considerations. Dr Stephanie Lippett

Palliative Care Out-of-hours. A resource pack for West Dorset. Contents:

Care of the Dying Management in Severe Renal Failure

What s New 2003? What new treatments? What have you discontinued? More information please!

Nausea and Vomiting in Palliative Care

Waterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC)

Implementing the recommendation on medication management and symptom control

BJF Acute Pain Team Formulary Group

Enhanced Community Palliative Support Services. Lynne Ghasemi St Luke s Hospice

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES

Opioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.

10/08/59 PAIN IS THE MOST COMMON TREATABLE SYMPTOM OF CANCER CURRENT EVIDENCE BASED CONCEPTS: MANAGEMENT OF CANCER PAIN PAIN AN UNMET CLINICAL NEED IN

End of Life Care. Dr Anne Garry Consultant in Palliative Medicine

EAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

ALLERGIES/ SENSITIVITIES This section must be completed before prescribing/administering any drug

Managing Care at End of Life:

BREATHLESSNESS MANAGEMENT

In our patients the cause of seizures can be broadly divided into structural and systemic causes.

Palliative and Hospice Care of the Terminally Ill Introduction

MND Just in Case kit Information for GPs

Q&A: Opioid Prescribing for Chronic Non-Malignant Pain

PALLIATIVE CARE PRESCRIBING FOR PATIENTS WHO ARE SUBSTANCE MISUSERS

GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi

PAIN & ANALGESIA. often accompanied by clinical depression. fibromyalgia, chronic fatigue, etc. COX 1, COX 2, and COX 3 (a variant of COX 1)

Berkshire West Area Prescribing Committee Guidance

Treating the symptoms of kidney failure

SYMPTOM CONTROL IN THE LAST DAYS OF LIFE. Bradford, Airedale, Wharfedale & Craven

Understanding pain in 5 minutes

PENNINE LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE

Agonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone

Breathlessness in advanced disease. February 2017

Approach to symptom control near the end-of-life

Gastrointestinal obstruction Dr Iain Lawrie

Nausea and Vomiting. Principles and Practice in End of Life Care November 2018

Narcotic Analgesics. Jacqueline Morgan March 22, 2017

Complicated pain. Dr Stephanie Lippett

SCOPING DOCUMENT FOR WHO Treatment Guidelines on pain related to cancer, HIV and other progressive life-threatening illnesses in adults

WR Fentanyl Symposium. Opioids, Overdose, and Fentanyls

SUBCUTANEOUS AS REQUIRED & SYRINGE PUMP PRESCRIPTION & ADMINISTRATION RECORD (SPAR) Name: Address: Postcode: Date of Birth: NHS Number:

PALLIATIVE CARE PRESCRIBING

Palliative Care. Pocketbook 4

Sam H Ahmedzai Academic Unit of Supportive Care Department of Oncology The University of Sheffield & Sheffield Teaching Hospitals NHS Foundation

We would like to thank you for completing this audit questionnaire which looks at how you manage nausea and vomiting in palliative care patients.

Pain Management Strategies Webinar/Teleconference

Guidelines for the Management of Chronic Non-Malignant Pain (CNMP) in Primary Care (not including neuropathic pain (NeP).

Opioid Pharmacology. Dr Ian Paterson, MA (Pharmacology), MB BS, FRCA, MAcadMEd. Consultant Anaesthetist Sheffield Teaching Hospitals

NHS Grampian Protocol For The Prescribing And Administration Of Oral Opioids Following Trauma Or Surgery

Eastern Health and Social Services Board Palliative Care

Transcription:

Symptom Management in the last weeks & days of life Facilitator: Vernon Davis RN/Community Team Leader Rowcroft Community Team

Session objectives To identify common symptoms at the end of life To increase confidence in assessing and managing symptoms working with priorities of care guidance To expand knowledge of pharmacological and nonpharmacological symptom control To compliment practical training on T34 ambulatory syringe pump

Priorities of Care for the Dying Person Published June 2014 by the LACDP (Leadership Alliance for the Care of Dying People) GMC,RCN,NICE, CQC, NHS England, et al One Chance to Get it Right document Five new Priorities of Care.

5 Priorities of Care The possibility that a person may die within the coming days/hours is recognised and communicated clearly, decisions about care are made in accordance with the person s needs/wishes and these are reviewed and revised regularly Sensitive communication takes place between staff and the person who is dying and those important to them The dying person and those important to them, are involved in decisions about treatment and care The people important to the dying person are listened to and their needs are respected Care is tailored to the individual and delivered with compassion with an individual care plan in place

So what are the more common symptom control issues?

Prevalence of Symptoms Pain Nausea Vomiting Dyspnoea Constipation Anorexia Weakness/Fatigue Anxiety Depression Insomnia

Principles of Symptom Control & End of life Care Assess LISTEN Communicate, discuss, explain, reassure. Prioritise (Who s priority?) Reverse the reversible Dying is inevitable: Are grandad s batteries running out? Give patient control where possible Don t limit treatment to drugs Prescribe prophylactically anticipate side effects Keep simple Seek advice Supervise REVIEW!!! REVIEW!!!

What are the challenges to symptom control/end of life care in your setting? Work In pairs

Palliative care interventions are a constant seeking of balance BURDEN BENEFIT

Legal issues in palliative care Doctrine of double effect - intention of benefit versus harm Evidence based practice versus best established practice - variations in practice - lack of research/inability to perform trials - lack of legal precedents

Did you know? 25% of all prescriptions used in palliative care are for licensed drugs used for unlicensed indication or given by unlicensed route

Palliative care prescribing Patient/family beliefs Expectations (Unrealistic. Grandad s batteries ) Fear of certain drugs (morphine, diamorphine, methadone) Fear of certain routes (subcutaneous syringe ) Keep simple risks of polypharmacy Palliation not cure Patient agenda v family agenda to cure versus palliate consent issues

Palliative care prescribing considerations Absorption Route Distribution Decreased plasma proteins ie liver damage due to metastases Decreased perfusion Changes in body mass and body fat Metabolism Decreased liver mass Decreased hepatic blood flow i.e. obstruction Chronic liver failure cirrhosis Decreased liver enzyme function Excretion Chronic renal failure Cardiac factors Decreased renal blood flow Weight loss

PAIN CONTROL

Misconceptions re. pain management Non drug treatments don t work Morphine is always the best drug Injections are stronger The patient must look in pain Morphine is addictive if taken for pain Morphine means the end is near

SQITARS Site Quality Intensity Timing Aggravating factors Relieving factors Secondary pain

Influences on pain Psychological Physical Spiritual Social

Spiritual factors influencing symptom control Perception of need for answers why is this happening? Feelings of pointlessness loss of hope Meaning of pain Regret/Self recrimination am I being punished? Doubt Spiritual isolation no-one understands Religious issues

Psychosocial influences on pain Anger Disfigurement Fear never assume cause Perceived helplessness Previous experiences of death, illness, pain Personality factors/ coping strategies Anxiety/ depression

Physical factors influencing pain Disease progression tumour invasion bone pain nerve compression nerve destruction muscle spasm colic ischaemic pain

Other physical factors influencing pain Other symptoms e.g. insomnia, depression, anxiety constipation etc Adverse effects of treatments Positional factors Incidental pain pain on movement, defaecation etc Other causes of exacerbations e.g. infection

Factors to increase pain threshold Companionship Other symptoms controlled Normality Treatments (understanding) Rest/sleep Other distractions Listening empathy/lessened anxiety CONTROL

Drug management of pain Step Ladder

Analgesic step ladder Non-opioid +/- adjuvant Weak opioid +/- adjuvant Strong opioid +/- adjuvant

Which opioid and why? How many do you know? Why were they used/chosen? Which ones would you not use/avoid in palliative care/ EOL care? Which one(s) is/are the drug of choice in known/end stage renal failure? (GFR <30ml/mim) What precautions do you need to take in renal failure? Can more than one opioid be used simultaneously? What are the common side effects of opioids?

Ready for some pharmacology?

Opioid receptors, ligands (agonists) & effects Receptors Mu (u) Delta (d) Kappa (k) ORL-1 Endogenous opioid Exogenous agonist Antagonist Effects B-endorphin Endomorphins Morphine (DM) Buprenorphine Fentanils Oxycodone Methadone Tapentadol Naloxone Naltrexone Analgesia Euphoria Confusion Sedation Nausea Constipation Resp dep Miosis Enkephalins Dynorphins Nociceptin Morphine (DM) Methadone Fentanils Buprenorphine Naloxone Similar to u but less marked Morphine (DM) Oxycodone Buprenorphine Naloxone Analgesia Aversion Diuresis Buprenorphine Mixed analgesia (spinal) and anti-opioid (brain)

Which opioid? Factors influencing choice Physician knowledge/confidence Availability of drug Patient preference Patient compliance Other patient-related factors e.g renal failure nausea & vomiting/bowel obstruction dysphagia

Morphine Acts within 30 minutes. Lasts around 4 hours Available as tablets, liquid, slow release oral forms, injection and suppository Starting dose in opioid naive patients 2.5-5mg every four hours of a non slow release formulation(less in elderly or frail). No maximum dose Oramorph 10mg/5ml not classed as CD! Drowsiness should decrease Breakthrough doses are vital and must be enough! Convert to slow release product when patient stabilised; still need breakthrough doses.

Side effects Nausea Constipation Sedation Myoclonus Hyperexcitability Respiratory depression

Morphine - side effect management Try to prevent Treat the side effect. - antiemetic, laxative Use alternative opioid Use non opioid May need antiemetic especially at first

MORPHINE Morphine - first line opiod Oral route where possible Regular administration by the clock + prn only prn means pain relief nil! Haloperidol prophylactic anti-emetic 5 days Injections do not increase effect - unless there is absorption /swallowing problem No addiction if has pain no ceiling dose Early use

Diamorphine Di-acetylmorphine, heroin Converted to morphine in body Much more soluble than morphine hence main use in syringe drivers More lipid soluble hence more potency than morphine by the injectable route

Oxycodone Can be useful as alternative in patients who HAVE developed side effects to morphine Studies give conflicting information Very expensive compared to morphine Subject to prescribing errors, mainly due to differing names and conversion factors Oxycontin, Oxynorm! Longtec, Shortec! Oxycodone orally up to twice as potent as morphine orally Oxycodone subcutaneously twice as potent as oxycodone orally May be of use in renal failure (?)

Opioids and renal impairment (egfr <30) Morphine - active metabolites excreted by the kidneys with increase in plasma ½ life leading to accumulation/toxicity. Not suitable in poor renal function Diamorphine - as for morphine Alfentanil - metabolised by the liver to inactive metabolites, excreted in urine. Drug of choice in poor renal function Fentanyl - as for alfentanil Buprenorphine - active metabolite excreted by kidneys but does not accumulate in renal failure Oxycodone - as for morphine

So, what about patches? What analgesic patches are available? When would you consider using/prescribing one? Which one would you consider? What are the advantages? What are the disadvantages? Good or bad thing at end of life? (in pairs)

Clinical indications for patches Difficulty or pain on swallowing Persistent nausea and/or vomiting Gastrointestinal obstruction Poor compliance with oral meds Tablet/morphine phobia Unacceptable morphine side-effects

Fentanyl v Buprenorphine Fentanyl Onset of action : 3-23 hours Time to peak plasma levels: 24-72 hours Onset of action (Butrans): 18-24 hrs 3 days! 60 hours! Onset of action (Transtec) : 11-21 hrs Plasma ½ life: 13-22 hours 13-35 hours 25-36 hours Duration of action: 72hours 7 days 4 days Patch strength: 12, 25, 37.5, 50, 75, 100mcg Morphine comparison (oral) in mg 30,60,90,120,180,240mgs/24hrs Buprenorphine 5, 10, 20mcg 35, 52.5, 70mcg 12, 24, 48mgs/24 hrs 84, 126, 168mgs/24hrs

4 HRS 24HRS MORPHINE (O) 10mg 60mg =30mg bd Oxycodone (O) 5mg 30mg = 15mg b.d. Buprenorphine patch Butrans 10+20mcg Fentanyl patch 25mcg every 72 hrs Morphine SC 5mg 30mg Oxycodone SC 2.5mg 15mg Diamorphine SC 2.5-5mg 20mg In all conversions there is uncertainty. Err on the side of caution

Adjuvant analgesics Tricyclic antidepressants: e.g. amitriptyline for nerve pain Anticonvulsants: e.g. gabapentin/pregabalin for nerve pain Steroids: e.g. dexamethasone for nerve root compression/raised ICP Bisphosphonates: e.g. pamidronate for Ca related bone pain Antispasmodics: e.g. buscopan for smooth muscle spasm Benzodiazepines: e.g diazepam for skeletal muscle spasm/cramps Antibiotics

Other treatments for control of pain TENS Surgery Chemotherapy Radiotherapy Diversion/meditation/imagery Massage/acupuncture/complementary therapy Nerve blocks/epidurals Topical analgesia

What about other symptoms?

Nausea Not necessarily the same as vomiting!!

Causes of nausea Anxiety Cerebral metastases Gastritis Constipation Biochemical disturbances hypercalcaemia, uraemia, hyponatraemia Obstruction Lessened gut mobility Treatments/drugs Infection

Drugs that may cause nausea Opioids often transient Antibiotics Antidepressants Radiotherapy/chemotherapy Anaesthetics NSAIDs Iron Steroids Digoxin Aminophylline Alcohol

Pathophysiology Chemical neurotransmiters conduct neural impulses connected to N/V Active in both gut and brain Stimulation of vomiting centre (VC) in brain stem triggers vomiting reflex VC receives input from gut (via vagus nerve), CTZ, Vestibular nuclei, and cerebral cortex Receptor sites involved: Serotonin/5HT (1,2,3,4 subtypes), Histamine/H1, Dopamine/D2, Acetylecholine/Achm, Neurokinin/NK1, Gamma-amniobutyric acid/gaba

Body area/receptor sites/agonists involved in vomiting pathway Gut Wall 5HT3, 5HT4, D2 Gastric irritants Abdo DXT Intestinal distension Chemo CTZ 5HT3,NK1,D 2 Morphine/ Digoxin Raised calcium Cerebral Cortex NK1,GABA,5 HT Vestibular nuclei AChm, H1 Fear/Anxiety Movement All Low sodium Vertigo of Antibiotics Raised ICP these Chemo Alcohol Vomiting centre Achm,H1,uopioid,5HT2, NK1 Feed into Uraemia Uraemia V Centre

Which antiemetic and why? Drug Receptor site affinity Main sites of action Domperidone D2 in gut Gut only, prokinetic. Metoclopramide D2 in gut and CTZ, 5HT4 in upper gut Central and prokinetic. Haloperidol Potent D2 in CTZ Central not prokinetic Cyclizine H1 and AChm Vestibular system and VC Granisetron, ondansetron Potent 5HT3 Central and gut Levomepromazine 5HT2, D2, AChm, H1 Central broad spectrum Hyoscine hydrobromide AChm Vestibular system and VC

Treatment of nausea Treat cause ie. Hypercalcaemia, pain, constipation Treat with antiemetic according to considered mechanism of nausea Combination therapy needed in 1/3 of patients Consider 2 birds with 1 stone i.e. treat insomnia and nausea use side effects to patient s advantage Anticipate and explain side effects

Non-pharmacological methods Reversible cause Sea bands/acupuncture Ginger NG tube (but consider carefully the implications? other options) Stents Radiotherapy MDT support e.g. OT for fatigue, SOB Relaxation/hypnotherapy Diversion Accupuncture

Restlessness and Agitation Recognise - change in behaviour reduced awareness increased purposeless movement fluctuating disorientation, confusion hallucinations, paranoid ideas mental distress

Restlessness and agitation - causes Physical Pain Full bladder Full rectum Breathless Cerebral metastases/dementia Mental anguish Fear Unfinished business Biochemical Liver or renal failure Raised calcium High/low glucose Hypoxia

Restlessness and agitation - management Treat the cause Treat the symptom Midazolam Haloperidol Levomepromazine General measures Nursing the patient - reassure, environment, safety Relatives - explanation

Respiratory secretions Inability to cough up/swallow secretions Recognise early at risk lung primary and secondary tumours head and neck tumours COPD pneumonia

Respiratory secretions - management Explanation and reassurance Nursing measures Position mouth care?suction Drugs Buscopan/Hyoscine Butylbromide Scopolamine/Hyoscine Hydrobromide Glycopyrolate

Breathlessness Affects 70% cancer patients in last 6 weeks of life and increases as death approaches More likely with Primary or secondary lung cancer Pleural disease Pre existing cardiopulmonary disease Terminal breathlessness - not reversible

Breathlessness: Management General measures Fan, open windows Mouth care Energy conservation Company/call button MDT approach (Physio/OT) Address fears, reassure

Breathlessness - management Drugs oxygen opiates: 4 hourly Oramorph, Diamorphine (Syringe pump) Benzodiazepines: Diazepam, Midazolam prn/sp

When do we need syringe pumps in palliative care?

Syringe pumps in palliative care.why? poor absorption nausea/ vomiting dysphagia confusion confidence concordance If none of above, symptom control may not improve with scsp consider reassessment/ management

Common drugs for subcutaneous syringe pumps?

Common SCSP drugs Diamorphine Haloperidol Metoclopramide Cyclizine Levomepromazine Hyoscine hydrobromide Buscopan Midazolam Octreotide

Sites. scapula abdomen chest arm leg

Site considerations ascites cachexia lymphoedema confusion concordance tumour site body image

What if site becomes inflamed?

What if site becomes inflamed seek advice increase diluent alternative drugs alternative routes Dexamethasone

Monitoring the syringe pump What to look for

Monitoring the SCSP light flashing crystallisation assess if infusing at correct rate assess time remaining check site document ASSESS SYMPTOM CONTROL

Key points to remember consider consent of patient/family takes up to 4 hours to be therapeutic - give loading dose ensure prn meds written for likely symptoms refer to guidelines seek advice

Common mistakes in symptom management Failure to distinguish between causes of symptom cancer and non-cancer Lack of attention to holistic issues/failure to use non-drug treatments Failure to assess each mechanismn individually and plan treatments separately Failure to anticipate, monitor and control unwanted side effects Failure to listen to patient and their agenda - terminology Chopping and changing regimens too quickly Reluctance to use morphine/awareness that pain may not be non-opiate responsive Fear of combining appropriate drugs/combining drugs inappropriately

What if symptom persists? Have basic principles of symptom control been followed Is diagnosis of mechanism correct Has new symptom developed Are there other factors exacerbating symptom Is patient concordant SEEK ADVICE

Summary of symptom control remember non cancer causes of symptoms assess each mechanism of the symptom separately and treat remember combination therapy may be needed remember non pharmacological methods encourage informed decisions monitor for efficacy versus side effects communicate with other members of MDT communicate with patient and family

MDT working seamless prescribing too many cooks! who is the key worker? availability of certain drugs out of hours access to palliative care Dynamic nature of progressive disease requires dynamic prescribing

South & West Devon Formulary Chapter 16 https://southwest.devonformularyguidance.nhs.uk/formulary/chapters/16.-palliative-care This is also available in an app for phones and ipads

Our ambition is for everyone across Torbay and South Devon to view this short film. The purpose of the video is to discover people's comfort in talking about death and dying. Talking about dying may not be easy, but could be one of the most important conversations you will ever have. Click on the picture to watch the 6 minute film

www.rowcroft.org.uk 01803 210800